Email Alert | RSS    帮助

中国防痨杂志 ›› 2026, Vol. 48 ›› Issue (5): 594-602.doi: 10.19982/j.issn.1000-6621.20250436

• 论著 • 上一篇    下一篇

长沙市耐多药/利福平耐药肺结核患者自付医疗费用及影响因素分析

谢赐福, 尹鹏亮, 宋丽新, 熊姿()   

  1. 长沙市疾病预防控制中心结核病防治科, 长沙 410004
  • 收稿日期:2025-11-10 出版日期:2026-05-10 发布日期:2026-04-27
  • 通信作者: 熊姿 E-mail:changshajfk@163.com
  • 基金资助:
    湖南省卫生健康委卫生科研课题(W20243059)

Analysis of out-of-pocket medical expenses and influencing factors of multidrug-resistant/rifampicin-resistant pulmonary tuberculosis patients in Changsha City

Xie Cifu, Yin Pengliang, Song Lixin, Xiong Zi()   

  1. Department of Tuberculosis Control, Changsha Center for Disease Control and Prevention, Changsha 410004, China
  • Received:2025-11-10 Online:2026-05-10 Published:2026-04-27
  • Contact: Xiong Zi E-mail:changshajfk@163.com
  • Supported by:
    Health Research Project of Hunan Provincial Health Commission(W20243059)

摘要:

目的: 分析长沙市耐多药/利福平耐药肺结核(multidrug resistant/rifampicin resistant tuberculosis, MDR/RR-PTB)患者自付医疗费用和影响因素,为优化MDR/RR-PTB患者医保政策和地方补助政策提供依据。方法: 对2020年1月1日至2024年12月31日在长沙市2家耐药结核病定点医院(湖南省胸科医院、长沙市中心医院)完成全疗程治疗的141例MDR/RR-PTB患者开展调查,通过“结核病管理信息系统”获取调查对象性别、年龄、职业、治疗分类等信息,通过问卷调查获取患者婚姻状况、文化程度、医保类型、家庭年收入等信息,通过医院信息管理系统获取患者分类、耐药类型、治疗方案、合并症、医疗费用及费用明细等信息,分析MDR/RR-PTB患者的自付医疗费用,采用逐步多重线性回归分析MDR/RR-PTB患者自付医疗费用的影响因素。结果: 141例MDR/RR-PTB患者全疗程医疗费用平均为185535元。其中,医保报销费用102594元、院内自付医疗费用57504元、院外自付医疗费用25437元,自付比例为44.7% (82941/185535);费用占比较高的为药品费125386元(67.6%)、化验费27058元(14.6%)、检查费4920元(2.7%)。逐步多重线性回归分析结果显示,单耐利福平肺结核患者的自付医疗费用是耐多药肺结核患者的1.21倍(95%CI: 1.03~1.42)。短程化疗方案和新版长程化疗方案(含贝达喹啉)的自付医疗费用分别是传统长程方案(不含贝达喹啉)的2.10倍(95%CI: 1.21~3.67)和1.45倍(95%CI: 1.23~1.70)。结论: 长沙市MDR/RR-PTB患者自付医疗费用较高,耐药类型和治疗方案是自付医疗费用的主要影响因素,亟需优化MDR/RR-PTB医保报销政策并出台地方补助政策。

关键词: 结核, 抗药性, 多药, 费用, 医疗, 因素分析, 统计学

Abstract:

Objective: With investigation on the out-of-pocket medical expenses and concerned influencing factors of multidrug-resistant/rifampicin-resistant pulmonary tuberculosis (MDR/RR-PTB) patients in Changsha City, to provide evidences for optimizing the medical insurance policies and local subsidy policies for MDR/RR-PTB patients. Methods: An investigation was conducted among 141 patients with MDR/RR-PTB who completed the full course of treatment in two designated drug-resistant tuberculosis hospitals in Changsha (Hunan Provincial Chest Hospital and Changsha Central Hospital) from January 1, 2020 to December 31, 2024. Data on the participants’ gender, age, occupation, and treatment classification were obtained through the Tuberculosis Information Management System. Meanwhile, data on marital status, educational level, type of medical insurance, and annual household income were collected via questionnaire surveys. In addition, data on patients’ classification, drug resistance type, treatment regimen, comorbidities, medical costs, and cost details were retrieved from the Hospital Information Management System. The medical expenses of patients were analyzed and stepwise multiple linear regression was used to analyze the influencing factors of out-of-pocket medical expenses for patients with MDR/RR-PTB. Results: The average medical costs of the full course treatment for the 141 MDR/RR-PTB patients were 185535 yuan, with 102594 yuan covered by medical insurance reimbursement, 57504 yuan out-of-pocket expenses incurred within the hospital, and 25437 yuan out-of-pocket expenses incurred outside the hospital. The out-of-pocket ratio was 44.7% (82941/185535). The medical costs with a relatively high proportion were 125386 yuan (67.6%) for medications, 27058 yuan (14.6%) for laboratory tests, and 4920 yuan (2.7%) for examinations. The results of stepwise multiple linear regression analysis showed that the out-of-pocket medical expenses for patients with rifampicin-monoresistant PTB were 1.21 (95%CI: 1.03-1.42) times as much as multidrug-resistant patients. The out-of-pocket expenses of the short-course chemotherapy regimen and the new long-course regimen (including Bdq) were 2.10 (95%CI: 1.21-3.67) times and 1.45 (95%CI: 1.23-1.70) times as much as those of the traditional long-course regimen (excluding Bdq), respectively. Conclusion: The out-of-pocket medical expenses of MDR/RR-PTB patients in Changsha city are relatively high, with drug resistance type and treatment regimen being the main influencing factors. It is urgent to optimize the medical insurance reimbursement policies for MDR/RR-PTB patients and introduce local subsidy policies as well.

Key words: Tuberculosis, Drug resistance, multiple, Fees, medical, Factor analysis, statistical

中图分类号: